Financing Will Support Development of TriCares' Tricuspid Valve Replacement System

 

July 2, 2018—TriCares SAS announced the successful completion of a €22 million ($25.4 million) Series B financing round, which will be used to advance product development, conduct clinical trials, and gain CE Mark approval in Europe for the company's transcatheter-based tricuspid valve replacement system. Founded in 2013, TriCares is a medical device start-up company headquartered in Paris, France, with an operating location in Munich, Germany.

The financing round was led by incoming investors Wellington Partners (Germany), Andera Partners (France), and BioMed Partners (Switzerland) and the existing French syndicate of CM-CIC Innovation, CapDecisif Management, and GO Capital.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.